Stock Lookup:   

The StockSpiker Daily 100 and Weekly 100 Covers The Biggest Movers In The Market    Click For The Latest Report

 
Geron Corporation (GERN)

Last Traded At:  $4.89     + $0.05
Volume:   642,033
Price/Earnings:   $0.00
Earnings Per Share:   ($0.73)
52 Week High:   $7.51
52 Week Low:   $4.37
StockSpiker Coverage & Performance
This stock has been covered by StockSpiker on the following dates. In addition, the percentage change from the coverage date and today's price is shown.
Coverage Coverage
Date
Gain Since Then
Top 100 Daily Gainers 8/2/2010: -24%
7/30/2010: -10%
Top 100 Daily Gainers 7/30/2010: -15%
1/4/2010: -27%
Top 100 Daily Gainers 6/30/2009: -57%
Top 100 Daily Losers 8/18/2009: -33%
Add GERN Email Alerts
Get an email or text alert anytime a stock appears on our Daily or Weekly 100 Report!
Email:
Ticker(s):  
About Geron Corporation
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. We are advancing telomerase targeted therapies, including an anti-cancer drug and a cancer vaccine, through multiple clinical trials. We are also the world leader in the development of human embryonic stem cell-based therapeutics, with our spinal cord injury treatment anticipated to be the first such product to enter clinical development. We were incorporated in 1990 under the laws of Delaware. Our principal executive offices are located at 230 Constitution Drive, Menlo Park, California 94025. Our telephone number is (650) 473-7700.

News For Geron Corporation
5/14/2010 11:30:00 AM Geron to Present at the Rodman & Renshaw Annual Global Healthcare Conference (Business Wire)
5/13/2010 6:20:55 PM UPDATE - Geron stem-cell therapy found safe in preclinical study (at Reuters)
5/13/2010 5:30:00 PM Geron Announces Positive Study Data on GRNCM1 (Business Wire)
5/12/2010 5:08:37 PM EU agency prepares to assess first stem cell drug (at Reuters)
5/4/2010 12:13:17 PM Wisconsin loses round in stem cell patent battle (AP)
5/3/2010 2:14:18 PM Geron Loss Narrows (Zacks.com)
4/30/2010 10:00:00 PM Geron Comments on Decision by U.S. PTO on WARF Patent (Business Wire)
4/30/2010 9:16:32 PM GERON CORP Files SEC form 10-Q, Quarterly Report (EDGAR Online)
4/30/2010 1:18:00 PM Tyvaso Forecasted To Be Significant Revenue Growth Driver For United Therapeutics (UTHR); Oral Formulation Undergoing Phase III Trials (Wall Street Transcript)
4/28/2010 8:30:00 PM Geron Corporation Reports 2010 First Quarter Financial Results and Highlights (Business Wire)

About Us |  FAQs |  Privacy Policy |  Terms & Conditions |  Contact Us Copyright © 2010 STOCK SPIKER LLC All Rights Reserved  

    

This website is intended to provide information only. If you are seeking advice on any matters relating to information on this website, you should - where appropriate - contact your broker or investment manager directly with your specific questions or seek advice from qualified Professional Financial advisor.

Whether you are a technical daytrader, or a long term fundamental investor, the StockSpiker gives you investment ideas based on the most relevant recent price history of stocks. Here are some recent movers that we have reported on:


Stock Lookup: